Inhibition of tumor growth and vasculature and fluorescence imaging using functionalized ruthenium-thiol protected selenium nanoparticles

Sun, Dongdong; Liu, Yanan; Yu, Qianqian; Qin, Xiuying; Yang, Licong; Zhou, Yanhui; Chen, Lanmei; Liu, Jie

doi:10.1016/j.biomaterials.2013.11.007

Cited by 123 publications

(61 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…24C). 276 Ru-MUA@Se directly suppressed HepG2 tumor growth, with no significant body weight loss, and also blocked blood vessel growth in vivo by decreasing microvessels. Ru-MUA@Se entered the cells via a clathrin-mediated endocytosis pathway.…”

Section: Ruthenium(ii)-based Nanomaterials Systemsmentioning

confidence: 94%

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

View full text Add to dashboard Cite

Cancer is rapidly becoming the top killer in the world. Most of the FDA approved anticancer drugs are organic molecules, while metallodrugs are very scarce. The advent of first metal based therapeutic agent, cisplatin, launched a new era in the application of transition metal complexes for therapeutic design. Due to their unique and versatile biochemical properties, ruthenium-based compounds have emerged as promising anti-cancer agents that serve as alternatives to cisplatin and its derivertives. The ruthenium(III) complexes have successfully been used in clinical research and their mechanisms of anticancer action have been reported in large volumes over the past few decades. Ruthenium(II) complexes have also attracted significant attention as anticancer candidates; however, only few of them have been reported comprehensively. In this review, we discuss the development of ruthenium(II) complexes as anticancer candidates and biocatalysts, including arene ruthenium complexes, polypyridyl ruthenium complexes, and ruthenium nanomaterial complexes. This review focuses on the likely mechanisms of action of ruthenium(II)-based anticancer drugs and the relationship between their chemical structures and biological properties. This review also highlights the catalytic activity and the photoinduced activation of ruthenium(II) complexes, their targeted delivery, and their activity in nanomaterial systems.

show abstract

Section: Ruthenium(ii)-based Nanomaterials Systemsmentioning

confidence: 94%

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Over the last several years, our group systematically researched the inhibition of tumor growth and angiogenesis using the functionalized selenium nanoparticles (SeNPs) of ruthenium (II) complexes [21, 22]. However, SeNPs are very unstable and easily aggregate when there are no other surfactants or stabilizers.…”

Section: Introductionmentioning

confidence: 99%

Mo polyoxometalate nanoparticles inhibit tumor growth and vascular endothelial growth factor induced angiogenesis

Zheng

Yang

Liu

et al. 2014

Science and Technology of Advanced Materials

Self Cite

View full text Add to dashboard Cite

Tumor growth depends on angiogenesis, which can furnish the oxygen and nutrients that proliferate tumor cells. Thus, blocking angiogenesis can be an effective strategy to inhibit tumor growth. In this work, three typical nanoparticles based on polyoxometalates (POMs) have been prepared; we investigated their capability as antitumor and anti-angiogenesis agents. We found that Mo POM nanoparticles, especially complex 3, inhibited the growth of human hepatocellular liver carcinoma cells (HepG2) through cellular reactive oxygen species levels’ elevation and mitochondrial membrane potential damage. Complex 3 also suppressed the proliferation, migration, and tube formation of endothelial cells in vitro and chicken chorioallantoic membrane development ex vivo. Furthermore, western blot analysis of cell signaling molecules indicated that Mo POMs blocked the vascular endothelial growth factor receptor 2-mediated ERK1/2 and AKT signaling pathways in endothelial cells. Using transmission electron microscopy, we demonstrated their cellular uptake and localization within the cytoplasm of HepG2 cells. These results indicate that, owing to the extraordinary physical and chemical properties, Mo POM nanoparticles can significantly inhibit tumor growth and angiogenesis, which makes them potential drug candidates in anticancer and anti-angiogenesis therapies.

show abstract

“…Ru-MUA@Se 50-80 [b] Angiogenesis inhibition, ROSg eneration, and mitochondrial membranepotential disruption HepG2 18.5 [d] [83] GA/Se/ RuNPs < 70 [b] MMP-2,9 protein inhibition,a poptosis induction…”

Section: Pristine/alloyed Metal Npsmentioning

confidence: 99%

Inherent Chemotherapeutic Anti‐Cancer Effects of Low‐Dimensional Nanomaterials

Zhou

Chu

et al. 2019

Chemistry A European J

View full text Add to dashboard Cite

Low-dimensional nanomaterials (LDNs) are receiving increasing attention in cancert herapy owing to their unique properties, especially the large surfacea rea-tovolume ratio. LDNs such as metallicn anoparticles (NPs), hydroxyapatite NPs, graphene derivatives, and black phosphorus (BP) nanosheets have been proposed for drug delivery, photothermal/photodynamic therapies, andm ultimodal theranostict reatments. The therapeutic effectiveness is mainly based on the physical characteristics of LDNs, but their inherent bioactivity has not been fully capitalized. In this Minireview,r ecent advances in the anti-cancer effects of varioust ypes of LDNs with inherentc hemotherapeutic bioactivity are described and the bioactivity mechanismsa re discussed on the cellular and molecular levels.B P, one of the newesta nd exciting members of the LDN family,i sh ighlighted owing to the excellent inherent bioactivity,s electivity,a nd biocompatibility in cancert herapy.L DNs and related derivatives possess inherentb ioactivity and selective chemotherapeutic effects suggesting large potentiala sn anostructured anti-cancer agentsinc ancer therapy.

show abstract

Inhibition of tumor growth and vasculature and fluorescence imaging using functionalized ruthenium-thiol protected selenium nanoparticles

Cited by 123 publications

References 35 publications

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

The development of anticancer ruthenium(ii) complexes: from single molecule compounds to nanomaterials

Mo polyoxometalate nanoparticles inhibit tumor growth and vascular endothelial growth factor induced angiogenesis

Inherent Chemotherapeutic Anti‐Cancer Effects of Low‐Dimensional Nanomaterials

Contact Info

Product

Resources

About